Octant

Octant is a biotechnology company that merges next-generation biology, chemistry, and computation to engineer precision small-molecule therapeutics targeting complex cellular mechanisms. The company focuses on correcting diseases of protein misfolding and mistrafficking, with a pipeline spanning genetic disease, oncology, metabolism, and immunology. Its lead candidate, OCT-980, is a first-in-disease oral small molecule for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), and a Phase 1a study in healthy volunteers was initiated in Q1 2026.

‍